Exhibiting at VIV Asia 2025

Vaksindo Animal Health, based in Bogor, Indonesia, is a pioneer in the production of veterinary vaccines and biologics. As the first local animal vaccine manufacturer in Indonesia, Vaksindo has over two decades of experience in providing high-quality animal health solutions to both domestic and international markets. The company operates as part of the Japfa Group, one of Asia’s leading agri-food companies, enabling extensive access to research infrastructure, advanced manufacturing, and global distribution networks.

Core Business and Product Portfolio

Vaksindo’s core competency lies in the development, production, and distribution of avian vaccines. Its robust portfolio is designed to protect poultry against common and economically devastating infectious diseases:

• Live Vaccines:

  • Vaksimune ND Clone – Protection against Newcastle Disease
  • Vaksimune IB – Infectious Bronchitis prevention
  • Vaksimune IBD M+ – Defense against Infectious Bursal Disease

• Inactivated Vaccines:

  • Vaksimune ND IB Inaktif – Inactivated vaccine against Newcastle and Infectious Bronchitis
  • Vaksimune NDL-IB Plus – Multivalent inactivated vaccine for broad-spectrum immunity

• Other Specialty Vaccines:

  • Vaksimune Pox – For fowlpox virus
  • Vaksimune Coryza LE – Targets Avibacterium paragallinarum

These vaccines are widely used in both industrial poultry operations and smallholder farms, with dosage forms optimized for mass administration.

Specialization and Core Strengths

Vaksindo has a strong foundation in veterinary virology, bacteriology, and immunology, which is reflected in their research-based product development. Core differentiators include:

• First Indonesian veterinary vaccine company with domestic R&D and production
• Vertical integration with the Japfa Group ensures a continuous loop of field trials, feedback, and formulation refinement
• Compliant with GMP and ISO 9001:2015 manufacturing standards
• Collaborations with veterinary research institutes and universities in Southeast Asia

The company is particularly focused on developing vaccines that meet tropical climate stability requirements and strain relevancy to local disease patterns.

International Presence and Shipment Records

Vaksindo has successfully expanded beyond Indonesia and now serves multiple countries in Southeast Asia and beyond. Trade and export records from platforms such as Volza and ImportYeti indicate:

• Active Export Markets: Vietnam, Bangladesh, Myanmar, India, Sri Lanka, Philippines
• Annual International Shipments: Estimated 150–200 vaccine consignments
• Key Exported Products: Vaksimune ND Clone, Vaksimune IB, Vaksimune IBD M+

Vaksindo also operates in Vietnam under Vaksindo Vietnam Animal Health, enabling on-ground distribution and support.

Financial Performance

Although standalone financial data for Vaksindo is not public, the backing of Japfa Group provides a strong financial and operational base. Japfa Ltd. reported:

• Revenue of over USD 4.7 billion in 2023
• Dedicated investment in biologics and veterinary health R&D across subsidiaries
• Continuous capital injection into vaccine production technologies, with specific investments into freeze-drying and virus propagation systems

These investments point to Vaksindo’s financial health and long-term commitment to animal healthcare innovation.

Certifications and Compliance

Vaksindo adheres to stringent regulatory frameworks for biological product safety and efficacy:

• Good Manufacturing Practice (GMP) certified facility
• ISO 9001:2015 Quality Management System
• All vaccines approved by the Directorate General of Livestock and Animal Health Services (DGLAHS) of Indonesia
• Compliance with importing country requirements including Vietnam, Bangladesh, and India

Vaksindo also performs post-market surveillance to ensure vaccine efficacy in real-world farm environments.

Target Market

Vaksindo’s primary customers include:

• Commercial poultry farms and integrators
• Veterinary distributors and pharmaceutical wholesalers
• Government animal health programs and cooperatives
• Smallholder poultry farmers through field agents and networks

Its vaccines are particularly aligned with the disease prevention needs of broilers, layers, and breeder flocks across tropical geographies.

Capabilities and Infrastructure

• Production Capacity: Over 1 billion doses per year across liquid and freeze-dried vaccine formats
• Facilities: Modern biological manufacturing plant in Bogor equipped with BSL-2 labs
• Packaging and Distribution: Cold chain storage systems and automated filling lines
• R&D Collaboration: Active cooperation with animal health research centers in Indonesia and Vietnam

Vaksindo continues to enhance its capabilities through investments in thermostable vaccine development and vector-based vaccine technologies.

Customer Testimonials

Farmers and integrators across Indonesia and Vietnam frequently cite Vaksindo’s vaccines for their reliability, improved flock immunity, and excellent after-sales support. The company's localized vaccine strains have earned trust for their high efficacy against endemic poultry diseases.

Achievements and Milestones

• First Indonesian manufacturer to export poultry vaccines to Vietnam
• Developed proprietary strains for Newcastle Disease and Infectious Bursal Disease
• Participated in major regional poultry health events such as ILDEX and VIV Asia
• Recognized by the Indonesian Ministry of Agriculture for contributions to livestock health innovation

With its blend of local innovation and international expansion, Vaksindo Animal Health is positioned as a trusted name in avian health across Asia.